Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

October 15, 2018

Quick Navi-Reader for Diagnosis of Influenza to be Launched in Japan

Otsuka Pharmaceutical Co., Ltd. will commence sales to medical institutions in Japan from October 23, 2018, of a medical instrument for the diagnosis of influenza, Quick Navi-Reader, a new product in the Quick Navi series of in vitro diagnostics.

This medical instrument improves on the best-selling Quick Navi-Flu diagnostic kit, with a faster and clearer display of results.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

Quick Navi-Reader for Diagnosis of Influenza to be Launched in Japan

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan